Learn how protein-level evidence can augment or replace genomic inference at critical drug development decision points.
Expert Q&A on how tumor protein profiling can de-risk oncology programs, delivering novel insights not inferred by genomics.
Bridging the gap between genomic target discovery & functional target validation that provides proof of mechanism.
Discovering novel functional markers that capture tumor biology, TME interactions, and drug response/resistance in archived tissue.
Using TAA profiling to identify differentially expressed, disease-modifying, tractable targets on the cell surface.
We touch on the key highlights related to methods used & discoveries made in our published study across >26K samples.
Why proteomics is critical to move beyond traditional known targets & biomarkers with mapping of non-canonical proteins.
How saliva proteomics enables patient-friendly trial design while delivering insights into systemic health & drug response.
See how Sapient & Rancho Biosciences have partnered to develop a clinical-molecular database combining omics & RWD at scale.
Explore advancements finally allowing drug developers to extract maximal biological insight from the plasma proteome.
Sapient joins experts from Boehringer Ingelheim, ASU, The Institute of Cancer Research, London, & SciLifeLab to discuss.
From Oxford Global's Multi-Omics Symposium, sharing examples of proteomics & metabolomics applied in drug discovery.
